

CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)

(Incorporated in the Republic of Singapore)

RECONSTITUTION OF THE BOARD AND BOARD COMMITTEES

The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”) wishes to announce the following changes with effect from 3 August 2026:

1. Cessation of Mr. Andrew John Lord as Lead Independent Director of the Company. Mr. Andrew John Lord will relinquish his position as Chairman of the Remuneration Committee and member of the Audit Committee and Nominating Committee.
2. Cessation of Mr. Mark Benedict Ryan as Independent Director of the Company. Mr. Mark Benedict Ryan will relinquish his position as Chairman of the Audit Committee and member of the Remuneration Committee and Nominating Committee.

The detailed announcements pursuant to Rule 704(6) of the Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”) in relation to the abovementioned cessations have been separately announced on SGXNET today.

The Board would like to express its sincere appreciation to Mr. Andrew John Lord and Mr. Mark Benedict Ryan for their invaluable contributions and dedicated service to the Company during their tenure.

3. Appointment of Mr. Wu Yu Liang, currently a Non-Executive and Independent Chairman of the Company, as Chairman of the Remuneration Committee.
4. Appointment of Mr. Lawrence Chen Tse Chau (Chen Shichao), currently an Independent Director of the Company, as Chairman of the Audit Committee. The Board considers Mr. Lawrence Chen Tse Chau (Chen Shichao) to be independent for the purposes of Rule 704(7) of the Catalist Rules.
5. Appointment of Mr. Vitters Sim Yu Xiong, currently a Non-Executive Non-Independent Director of the Company, as member of the Audit Committee, Remuneration Committee and Nominating Committee. The Board does not consider Mr. Vitters Sim Yu Xiong to be independent for the purposes of Rule 704(7) of the Catalist Rules.

Following the abovementioned changes, the composition of the Board and Board Committees of the Company shall be reconstituted effective from 3 August 2026 as follows:

Board

Mr. Wu Yu Liang	Non-Executive and Independent Chairman
Mr. Ong Choon Yi (Wang Junyi)	Executive Director and Group Chief Executive Officer
Mr. Lawrence Chen Tse Chau (Chen Shichao)	Independent Director
Mr. Yee Pinh Jeremy	Non-Executive Non-Independent Director
Mr. Vitters Sim Yu Xiong	Non-Executive Non-Independent Director

Audit Committee

Mr. Lawrence Chen Tse Chau (Chen Shichao)	(Chairman)
Mr. Wu Yu Liang	(Member)
Mr. Vitters Sim Yu Xiong	(Member)

Nominating Committee

Mr. Wu Yu Liang	(Chairman)
Mr. Lawrence Chen Tse Chau (Chen Shichao)	(Member)
Mr. Vitters Sim Yu Xiong	(Member)

Remuneration Committee

Mr. Wu Yu Liang	(Chairman)
Mr. Lawrence Chen Tse Chau (Chen Shichao)	(Member)
Mr. Vitters Sim Yu Xiong	(Member)

By Order of the Board

Ong Choon Yi (Wang Junyi)
Executive Director and Group Chief Executive Officer

3 August 2026

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.